Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Doshi

Showing results (91-100 of 144) with videos related to

Pageof 15
Sort By:
Clinical Trials (London, England)|April 13, 2023
Definition and rationale for placebo composition: Cross-sectional analysis of randomized trials and protocols published in high-impact medical journalsKyungwan Hong, Anisa Rowhani-Farid, Peter Doshi
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 16, 2017
Findings of an Observational Study of Neuraminidase Inhibitors Highly Sensitive to Decision to Exclude 1652 Treated PatientsMark Jones, Chris Del Mar, Peter Doshi
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|May 10, 2017
Pharmacists can help to end direct-to-consumer advertisingAida Kuzucan, Peter Doshi, Julie M Zito
The New England Journal of Medicine|January 19, 2018
Noninferiority TrialsPeter Doshi, O'Mareen Spence, John H Powers
Mayo Clinic Proceedings|December 5, 2020
Antibiotics Approved for Marketing in Populations Specifically Excluded From Premarketing Trials, 1999-2018Aida Kuzucan, John H Powers, Peter Doshi
JAMA Internal Medicine|March 3, 2020
Integrated Drug Reviews at the US Food and Drug Administration-Legal Concerns and Knowledge LostMatthew Herder, Christopher J Morten, Peter Doshi
Plos Medicine|April 17, 2012
The imperative to share clinical study reports: recommendations from the Tamiflu experiencePeter Doshi, Tom Jefferson, Chris Del Mar
BMJ (Clinical Research Ed.)|September 27, 2015
Are manufacturers sharing data as promised?Evan Mayo-Wilson, Peter Doshi, Kay Dickersin
JAMA Internal Medicine|July 31, 2020
Integrated Drug Reviews at the US Food and Drug Administration-ReplyPeter Doshi, Christopher J Morten, Matthew Herder
Drug Safety|November 10, 2012
Neuropsychiatric adverse events and oseltamivir for prophylaxisMark Jones, Rokuro Hama, Tom Jefferson, et al.
Pageof 15

Showing results (91-100 of 144) with videos related to

Sort By:
Pageof 15
Clinical Trials (London, England)|April 13, 2023
Definition and rationale for placebo composition: Cross-sectional analysis of randomized trials and protocols published in high-impact medical journalsKyungwan Hong, Anisa Rowhani-Farid, Peter Doshi
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 16, 2017
Findings of an Observational Study of Neuraminidase Inhibitors Highly Sensitive to Decision to Exclude 1652 Treated PatientsMark Jones, Chris Del Mar, Peter Doshi
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|May 10, 2017
Pharmacists can help to end direct-to-consumer advertisingAida Kuzucan, Peter Doshi, Julie M Zito
The New England Journal of Medicine|January 19, 2018
Noninferiority TrialsPeter Doshi, O'Mareen Spence, John H Powers
Mayo Clinic Proceedings|December 5, 2020
Antibiotics Approved for Marketing in Populations Specifically Excluded From Premarketing Trials, 1999-2018Aida Kuzucan, John H Powers, Peter Doshi
JAMA Internal Medicine|March 3, 2020
Integrated Drug Reviews at the US Food and Drug Administration-Legal Concerns and Knowledge LostMatthew Herder, Christopher J Morten, Peter Doshi
Plos Medicine|April 17, 2012
The imperative to share clinical study reports: recommendations from the Tamiflu experiencePeter Doshi, Tom Jefferson, Chris Del Mar
BMJ (Clinical Research Ed.)|September 27, 2015
Are manufacturers sharing data as promised?Evan Mayo-Wilson, Peter Doshi, Kay Dickersin
JAMA Internal Medicine|July 31, 2020
Integrated Drug Reviews at the US Food and Drug Administration-ReplyPeter Doshi, Christopher J Morten, Matthew Herder
Drug Safety|November 10, 2012
Neuropsychiatric adverse events and oseltamivir for prophylaxisMark Jones, Rokuro Hama, Tom Jefferson, et al.
Pageof 15